Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023GlobeNewsWire • 05/19/23
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023GlobeNewsWire • 05/04/23
Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/29/23
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/29/23
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023GlobeNewsWire • 03/22/23
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical TrialGlobeNewsWire • 03/16/23
Journey Medical Corporation to Participate in the 35th Annual ROTH ConferenceGlobeNewsWire • 03/07/23
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial OfficerGlobeNewsWire • 01/20/23
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaGlobeNewsWire • 01/10/23
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29GlobeNewsWire • 12/20/22
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceGlobeNewsWire • 12/05/22
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/22
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/22
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 11/03/22
Journey Medical Corporation to Participate in Upcoming October 2022 Investor ConferencesGlobeNewsWire • 10/04/22
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaGlobeNewsWire • 08/30/22
Journey Medical Corporation (DERM) CEO Claude Maraoui on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/09/22
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/09/22
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent ExclusivityGlobeNewsWire • 05/24/22
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor ConferenceGlobeNewsWire • 05/23/22
Journey Medical Corporation (DERM) CEO Claude Maraoui on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/15/22
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/10/22